Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2025)

Historic FCF Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 2135.38%.

  • Insight Molecular Diagnostics' FCF Margin rose 27489600.0% to 2135.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 543.71%, marking a year-over-year increase of 23234300.0%. This contributed to the annual value of 1128.6% for FY2024, which is 4419900.0% up from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported FCF Margin of 2135.38% as of Q3 2025, which was up 27489600.0% from 1279.54% recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' FCF Margin registered a high of 208.02% during Q4 2021, and its lowest value of 18291.04% during Q3 2022.
  • Its 5-year average for FCF Margin is 2878.9%, with a median of 1475.59% in 2023.
  • As far as peak fluctuations go, Insight Molecular Diagnostics' FCF Margin surged by 422625900bps in 2021, and later plummeted by -171382000bps in 2022.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' FCF Margin stood at 208.02% in 2021, then tumbled by -1733bps to 3813.87% in 2022, then soared by 61bps to 1492.99% in 2023, then surged by 75bps to 376.11% in 2024, then crashed by -468bps to 2135.38% in 2025.
  • Its last three reported values are 2135.38% in Q3 2025, 1279.54% for Q2 2025, and 288.35% during Q1 2025.